HCPCS Level II · Miscellaneous services (temporary codes)
Q5098Injection, ustekinumab-srlf (imuldosa), biosimilar, 1 mg
✓ Active
Source: CMS HCPCS quarterly update, October 2026. Page updated September 29, 2026.
About Q5098
Q5098 is an HCPCS Level II code in the Q series (miscellaneous services (temporary codes)), describing injection, ustekinumab-srlf (imuldosa), biosimilar, 1 mg.
It was added to HCPCS effective 07/01/2025, and its current record took effect 07/01/2026.
Its Medicare coverage code is "C", meaning coverage is left to the Medicare contractor's judgment.
Details
- Short description
- Inj ustekinumab-srlf, 1 mg
- Date added
- 07/01/2025
- Action effective
- 07/01/2026
- BETOS
- O1E
Related Q50xx codes
- Q5001Hospice or home health care provided in patient's home/residence
- Q5002Hospice or home health care provided in assisted living facility
- Q5003Hospice care provided in nursing long term care facility (ltc) or non-skilled nursing facility (nf)
- Q5004Hospice care provided in skilled nursing facility (snf)
- Q5005Hospice care provided in inpatient hospital
- Q5006Hospice care provided in inpatient hospice facility
- Q5007Hospice care provided in long term care facility
- Q5008Hospice care provided in inpatient psychiatric facility
- Q5009Hospice or home health care provided in place not otherwise specified (nos)
- Q5010Hospice home care provided in a hospice facility
- Q5099Injection, ustekinumab-stba (steqeyma), biosimilar, 1 mg
Common questions about Q5098
Is HCPCS Q5098 still valid?
- Yes. Q5098 is active in the CMS October 2026 HCPCS file.
Does Medicare cover Q5098?
- Its coverage code is "C": coverage is left to the Medicare contractor's judgment. Check the local coverage determination for your region.